It is well established that smoking is the primary preventable cause of disease and death in the United States and that it is responsible for a wide range of negative health consequences, including but not limited to respiratory disease. According to the US Public Health Service, all patients attempting to quit smoking should be encouraged to use one or more effective pharmacotherapy agents for cessation except in the presence of special circumstances or in populations for which there is insufficient evidence of effectiveness (pregnant women, smokeless tobacco users, light smokers and adolescents). These medications are most effective when coupled with behavioral counseling interventions. This review article provides an overview of comprehensive (the 5 A’s framework: Ask, Advise, Assess, Assist, Arrange) and brief (Ask, Advise, Refer) interventions for assisting patients with quitting, and a more detailed review of the seven first-line pharmacological agents for smoking cessation (nicotine replacement therapy formulations, bupropion SR and varenicline) and combination therapy regimens. This information will facilitate respiratory therapists in addressing the most important risk factor for pulmonary disease in the patient population that they serve.
American Cancer Society(2009). Cancer Facts & Figures (2009), American Cancer Society : Atlanta, GA.
2.
Bars, M.P., Banauch, G.I., Appel, D., Andreachi, M., Mouren, P., Kelly, K.J. et al. (2006) Tobacco Free with FDNY: The New York City Fire Department World Trade Center Tobacco Cessation Study. Chest129: 979-987.
3.
Benowitz, N. and Dempsey, D. ( 2004) Pharmacotherapy for smoking cessation during pregnancy . Nicotine Tob Res6(Suppl. 2): S189-202.
4.
Benowitz, N.L. ( 2003) Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis46: 91-111.
5.
Benowitz, N.L. ( 2009) Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol49: 57-71.
6.
Benowitz, N.L., Hukkanen, J. and Jacob 3rd, P. ( 2009) Nicotine chemistry, metabolism, kinetics and biomarkers . Handb Exp Pharmacol29-60.
7.
Benowitz, N.L., Zevin, S. and Jacob, P. ( 1997) Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking . Br J Clin Pharmacol43: 259-267.
8.
Cahill, K., Stead, L.F. and Lancaster, T. ( 2008) Nicotine receptor partial agonists for smoking cessation . Cochrane Database Syst RevCD006103.
9.
CDC (2008a) Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000-2004. MMWR57: 1226-1228.
10.
CDC (2008b) Cigarette smoking among adults - United States, 2007. MMWR57: 1221-1226.
11.
Coe, J.W., Brooks, P.R., Vetelino, M.G., Wirtz, M.C., Arnold, E.P., Huang, J. et al. (2005) Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem48: 3474-3477.
12.
Cosio, M.G., Saetta, M. and Agusti, A.(2009) Immunologic aspects of chronic obstructuve pulmonary disease . N Engl J Med360: 2445-2454.
13.
Ebbert, J.O., Burke, V.M., Hays, J.T. and Hurt, R.D.(2009a) Combination treatment with varenicline and nicotine replacement therapy . Nicotine Tob Res11: 572-576.
14.
Ebbert, J.O., Croghan, I.T., Sood, A., Schroeder, D.R., Hays, J.T. and Hurt, R.D.(2009b) Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res11: 234-239.
15.
Fiore, M.C., Jaén, C.R., Baker, T.B., Bailey, W.C., Benowitz, N.L., Curry, S.J. et al. (2008) Treating Tobacco Use and Dependence: 2008 Update . Clinical Practice Guideline, U.S. Department of Health and Human Services: Rockville, MD.
16.
Food and Drug Administration (FDA) (2009) Information for healthcare professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm
17.
Foulds, J. ( 2006) The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. Int J Clin Pract60: 571-576.
18.
GlaxoSmithKline Inc. (2009) Zyban Package Insert. Research Triangle Park, NC.
19.
GOLD (Global Initiative for Chronic Obstructive Lung Disease) (2008) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2008 . Available at: http://www.goldcopd.com/
20.
Gourlay, S.G., Stead, L.F. and Benowitz, N.L. ( 2004) Clonidine for smoking cessation. Cochrane Database Syst Rev CD000058.
21.
Hughes, J.R., Stead, L.F. and Lancaster, T. ( 2007) Antidepressants for smoking cessation. Cochrane Database Syst RevCD000031.
22.
Hurt, R.D., Dale, L.C., Offord, K.P., Lauger, G.G., Baskin, L.B., Lawson, G.M. et al. (1993) Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther54: 98-106.
23.
Joseph, A.M. and Fu, S.S. ( 2003) Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. Prog Cardiovasc Dis45: 429-441.
24.
Kamholz, S.L. ( 2004) Pulmonary and cardiovascular consequences of smoking . Med Clin North Am88: 1415-1430.
25.
Lawson, G.M., Hurt, R.D., Dale, L.C., Offord, K.P., Croghan, I. T., Schroeder, D.R. et al. (1998)
26.
Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol38: 502-509.
27.
Mokdad, A.H., Marks, J.S., Stroup, D.F. and Gerberding, J.L. ( 2004) Actual causes of Death in the United States, 2000. JAMA291: 1238-1245.
28.
McRobbie, H. and Hajek, P. ( 2001) Nicotine replacement therapy in patients with cardiovascular disease: guidelines for health professionals. Addiction96: 1547-1551.
29.
National Cancer Institute (2001) Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and Tobacco Control Monograph No. 13. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Pub. No. 02-5074: Bethesda, MD.
30.
Pfizer, Inc. (2009) Chantix Package Insert. New York, NY.
31.
Rx for Change: Clinician-Assisted Tobacco Cessation.University of California San Francisco: San Francisco, CA, 2009.
32.
Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary . Am J Respir Crit Care Med176: 532-555.
33.
Slemmer, J.E., Martin, B.R. and Damaj, I.M. ( 2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther295: 321-327.
34.
Stead, L.F., Perera, R., Bullen, C., Mant, D. and Lancaster, T. ( 2008) Nicotine replacement therapy for smoking cessation . Cochrane Database Syst RevCD000146.
Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med150: 447-454.
37.
Tomlinson, J.E., McMahon, A.D., Chaudhuri, R., Thompson, J.M., Wood, S.F. and Thomson, N.C. ( 2005) Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax60: 282-287.
38.
Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence, Baker, T.B., Piper, M.E., McCarthy, D.E., Bolt, D.M., Smith, S.S., Kim, S.Y. et al. (2007) Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res9 (Suppl. 4): S555-70.
39.
Usdhss (1994) Prventing Tobacco Use Among Young People: A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking Health.
40.
Usdhhs (2004). The Health Consequences of Smoking: A Report of theSurgeon General, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Bethesda, MD.
41.
World Health Organization(2008). WHO Report on the Global Tobacco Epidemic, 2008: The mPOWER Package, World Health Organization: Geneva.
42.
Zhu, S., Melcer, T., Sun, J., Rosbrook, B. and Pierce, J.P. ( 2000) Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med18: 305-311.
43.
Zhu, S.H., Anderson, C.M., Tedeschi, G.J., Rosbrook, B., Johnson, C.E., Byrd, M. et al. (2002) Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med347: 1087-1093.
